Business Wire

CA-ENCHROMA-INC

1.9.2022 20:05:34 CEST | Business Wire | Press release

Share
EnChroma Launches International Color Blindness Awareness Month

EnChroma, Inc. – creators of glasses for color blindness – today announced the launch of International Color Blindness Awareness Month. During the entire month of September, EnChroma and over 50 museums, libraries, school districts, state and federal parks, universities, tourism agencies, and Lions and Kiwanis Clubs will make social media posts and publish other communications designed to educate their members, students, communities and/or followers about Color Vision Deficiency (CVD, or “color blindness”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005741/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Image courtesy of EnChroma @enchroma

“We are pleased that so many esteemed institutions have joined EnChroma to promote International Color Blindness Month to educate the world about the impact color vision deficiency has on people at work, in school, and in fully appreciating art or the colors of nature,” said Erik Ritchie, CEO of EnChroma. “More awareness will result in fewer daily frustrations for color blind people and more accessibility.”

Color blindness affects one in 12 men (8%) and one in 200 women (.5%); 350 million people worldwide. While people with normal color vision see over one million shades of color, those with Color Vision Deficiency only see an estimated 10% of hues and shades. Common color confusions include green and yellow, gray and pink, purple and blue, and red can appear brown. Click here for images depicting color blindness.

The 50+ organizations supporting International Color Blindness Month include:

• Georgia O'Keeffe Museum, NM

• Boston University, MA

• Faber-Castell, Germany

• North Carolina State University, NC

• Birmingham Museum of Art, AL

• Anythink Libraries, CO

• Museum of Contemporary Art Denver

• Penn State University, Forensic Science Dept., PA

• J.N. "Ding" Darling National Wildlife Refuge, FL

• Fondazione Paolina Brugnatelli, Milan, Italy

• Lions Club, District L, NC

• Clinton-Macomb Public Library, MI

• Cantigny Park, IL

• Nelson-Atkins Museum of Art, MO

• School District of New London, WI

• Nahant Public Library, MA

• Johnson County Public Library, IN

• Dallas Museum of Art, TX

• Lions Club, Adams, MN

• RISD, Museum of Art, Rhode Island School of Design, RI

• St. Johns County Public Libraries, FL

• Alfred University, NY

• Museum of Fine Arts, St. Petersburg, FL

• i.d.e.a. Museum, AZ

• Central High School (D301), IL

• Kiwanis Club of Findlay, OH

• Shelburne Museum, VT

• Glen Ridge Public Library, NJ

• Lions Club, District I, NC

• Downers Grove Public Library, IL

• National Museum of Wildlife Art, WY

• Motlow State Community College, TN

• Mulvane Art Museum, KS

• Lions Club, District S, NC

• Albrecht-Kemper Museum of Art, MO

• Spiva Center for the Arts, MO

• Eye See Color Project, FL

• Helsingin Optiikka Oy, Finland

• Plainfield Area Public Library, IN

• Evansville Vanderburgh Public Library, IN

•Technology Aids for the Blind & Visually Impaired, NC

 

• Lions Club, District O, NC

• Unique Optiek BV, The Netherlands

• Lions Club, District N, NC

• Carolyn Campagna Kleefeld Contemporary Art Museum, CA

• Jonathan Jones Color Blind Fund, AZ

EnChroma encourages other organizations and individuals to promote color blindness awareness anytime in September by posting to social media, websites and other forums using any of the templates located here, and/or images showing the color blind view of various settings here.

EnChroma Color Accessibility Program

EnChroma continues to lead in advocating for “color accessibility” through its EnChroma Color Accessibility Program, in which over 150 organizations participate. The program helps public venues such as schools, state parks, libraries, museums, tourism bureaus, resorts and other organizations loan EnChroma glasses to color blind students and guests to help make schoolwork that involves color, colorful exhibits, attractions and/or experiences accessible to the color blind.

Through the program, EnChroma donates a pair of glasses to an organization for every pair it purchases. Materials to educate teachers, parents, employers and others about color blindness, and how to support color blind students, children, employees and visitors, are also provided. EnChroma encourages schools to easily and quickly test all students for color blindness using its free online color vision test. Email accessibility@enchroma.com to learn about the program.

EnChroma’s patented lens technology helps people with red-green color blindness see an expanded range of colors and see them more vibrantly, clearly and distinctly. Studies by world-renowned color vision scientists at the University of California, Davis and France’s INSERM Stem Cell and Brain Research Institute, and the University of the Incarnate Word, have demonstrated the effectiveness of EnChroma glasses.

Story Assets for Media

Visit our Media Kit to download user videos, photos of EnChroma glasses and b-roll.

About EnChroma

Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Visit enchroma.com to learn more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005741/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye